Synchronous splenectomy and hepatectomy for patients with hepatocellular carcinoma and hypersplenism: A casecontrol study

World Journal of Gastroenterology

Volumn 21, Issue 8, 2015, Pages 2358-2366

  Zhang, Xiao Yun ^a   Li, Chuan ^a   Wen, Tian Fu ^a   Yan, Lu Nan ^a   Li, Bo ^a   Yang, Jia Yin ^a   Wang, Wen Tao ^a   Jiang, Li ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Case control study; Hepatectomy; Hepatocellular carcinoma; Hypersplenism; Splenectomy

Indexed keywords

ABDOMINAL BLEEDING; ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HYPERSPLENISM; HYPOTENSION; LAPAROTOMY; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLEURA EFFUSION; RESPIRATORY FAILURE; SHOCK; SPLENECTOMY; SPLENOMEGALY; THORACOCENTESIS; THROMBOCYTE COUNT; TUMOR VOLUME; ADVERSE EFFECTS; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; CHINA; KAPLAN MEIER METHOD; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; POSTOPERATIVE COMPLICATIONS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHINA; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; HYPERSPLENISM; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE COMPLICATIONS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SPLENECTOMY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923799438     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i8.2358     Document Type: Article

References (36)

1. Sugawara Y, Yamamoto J, Shimada K, Yamasaki S, Kosuge T, Takayama T, Makuuchi M. Splenectomy in patients with hepatocellular carcinoma and hypersplenism. J Am Coll Surg 2000; 190: 446-450 [PMID: 10757382 DOI: 10.1016/S1072-7515(99)00294-X]
2. Lau WY. Management of hepatocellular carcinoma. J R Coll Surg Edinb 2002; 47: 389-399 [PMID: 11874260]
3. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000; 191: 38-46 [PMID: 10898182 DOI: dx.doi.org/10.1016/ S1072-7515(00)00261-1]
4. Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, Wong J. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001; 234: 63-70 [PMID: 11420484 DOI: 10.1097/00000658-2 00107000-00010]
5. Dimick JB, Cowan JA, Knol JA, Upchurch GR. Hepatic resection in the United States: Indications, outcomes, and hospital procedural volumes from a nationally representative database. Arch Surg 2003; 138: 185-191 [PMID: 12578418 DOI: 10.1001/archsurg.138.2.185]
6. Looke DF, Runnegar NJ. Splenectomy and sepsis. Med J Aust 2012; 196: 587 [PMID: 22621151 DOI: 10.5694/mja12.10587]
7. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]
8. Jasnis MA, Elján AM, Oisgold-Dagá S. Regulation of tumor growth by soluble spleen factors: effect of tumor resection. J Surg Oncol 1987; 35: 139-145 [PMID: 3586684 DOI: 10.1002/jso.2930350216]
9. Nomura Y, Kage M, Ogata T, Kondou R, Kinoshita H, Ohshima K, Yano H. Influence of splenectomy in patients with liver cirrhosis and hypersplenism. Hepatol Res 2014; 44: E100-E109 [PMID: 24033833 DOI: 10.1111/hepr.12234]
10. Amin MA, el-Gendy MM, Dawoud IE, Shoma A, Negm AM, Amer TA. Partial splenic embolization versus splenectomy for the management of hypersplenism in cirrhotic patients. World J Surg 2009; 33: 1702-1710 [PMID: 19513783 DOI: 10.1007/ s00268-009-0095-2]
11. Shimada M, Hashizume M, Shirabe K, Takenaka K, Sugimachi K. A new surgical strategy for cirrhotic patients with hepatocellular carcinoma and hypersplenism. Performing a hepatectomy after a laparoscopic splenectomy. Surg Endosc 2000; 14: 127-130 [PMID: 10656943 DOI: 10.1007/s004649900082]
12. Torzilli G, Makuuchi M, Inoue K, Takayama T, Sakamoto Y, Sugawara Y, Kubota K, Zucchi A. No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: Is there a way? A prospective analysis of our approach. Arch Surg 1999; 134: 984-992 [PMID: 10487594 DOI: 10.1001/archsurg.134.9.984]
13. Rees M, Plant G, Wells J, Bygrave S. One hundred and fifty hepatic resections: evolution of technique towards bloodless surgery. Br J Surg 1996; 83: 1526-1529 [PMID: 9014666]
14. Grazi GL, Ercolani G, Pierangeli F, Del Gaudio M, Cescon M, Cavallari A, Mazziotti A. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg 2001; 234: 71-78 [PMID: 11420485 DOI: 10.1097/ 00000658-200107000-00011]
15. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943 [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001]
16. Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K, Imamura H, Sugawara Y, Kokudo N, Makuuchi M. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008; 134: 1908-1916 [PMID: 18549877 DOI: 10.1053/j.gastro.2008.02.091]
17. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434-1440 [PMID: 10573522 DOI: 10.1002/hep.510300629]
18. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, Makuuchi M, Nakamura Y, Okita K, Yamada R. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32: 1224-1229 [PMID: 11093728 DOI: 10.1053/jhep.2000.20456]
19. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240: 205-213 [PMID: 15273542 DOI: 10.1097/01.sla.0000133083.54934.ae]
20. Wang Q, Sun K, Li XH, Peng BG, Liang LJ. Surgical treatment for hepatocellular carcinoma and secondary hypersplenism. Hepatobiliary Pancreat Dis Int 2006; 5: 396-400 [PMID: 16911938]
21. Paquet KJ. Surgery for cirrhotic patients with hepatocellular carcinoma and hypersplenism. Surg Endosc 2001; 15: 104-105 [PMID: 11178775 DOI: 10.1007/s004640000277]
22. Aoe T, Okamoto Y, Saito T. Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J Exp Med 1995; 181: 1881-1886 [PMID: 7722462]
23. Ugel S, Peranzoni E, Desantis G, Chioda M, Walter S, Weinschenk T, Ochando JC, Cabrelle A, Mandruzzato S, Bronte V. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep 2012; 2: 628-639 [PMID: 22959433 DOI: 10.1016/j.celrep.2012.08.006]
24. Karakantza M, Mouzaki A, Theodoropoulou M, Bussel JB, Maniatis A. Th1 and Th2 cytokines in a patient with Evans' syndrome and profound lymphopenia. Br J Haematol 2000; 110: 968-970 [PMID: 11054090 DOI: 10.1046/j.1365-2141.2000.02296.x]
25. Hashimoto N, Shimoda S, Kawanaka H, Tsuneyama K, Uehara H, Akahoshi T, Kinjo N, Taketomi A, Shirabe K, Akashi K, Lleo A, Ansari AA, Gershwin ME, Maehara Y. Modulation of CD4+ T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis. Clin Exp Immunol 2011; 165: 243-250 [PMID: 21615390 DOI: 10.1111/j.1365-2249.2011.04393.x]
26. Chen XP, Wu ZD, Huang ZY, Qiu FZ. Use of hepatectomy and splenectomy to treat hepatocellular carcinoma with cirrhotic hypersplenism. Br J Surg 2005; 92: 334-339 [PMID: 15672441 DOI: 10.1002/bjs.4776]
27. Morinaga A, Ogata T, Kage M, Kinoshita H, Aoyagi S. Comparison of liver regeneration after a splenectomy and splenic artery ligation in a dimethylnitrosamine-induced cirrhotic rat model. HPB (Oxford) 2010; 12: 22-30 [PMID: 20495641 DOI: 10.1111/ j.1477-2574.2009.00116.x]
28. Akahoshi T, Hashizume M, Tanoue K, Shimabukuro R, Gotoh N, Tomikawa M, Sugimachi K. Role of the spleen in liver fibrosis in rats may be mediated by transforming growth factor beta-1. J Gastroenterol Hepatol 2002; 17: 59-65 [PMID: 11895554 DOI: 10.1046/j.1440-1746.2002.02667.x]
29. Ueda S, Yamanoi A, Hishikawa Y, Dhar DK, Tachibana M, Nagasue N. Transforming growth factor-beta1 released from the spleen exerts a growth inhibitory effect on liver regeneration in rats. Lab Invest 2003; 83: 1595-1603 [PMID: 14615413 DOI: 10.1097/01. LAB.0000095686.10639.C8]
30. Marra F, Tacke F. Roles for chemokines in liver disease. Gastroenterology 2014; 147: 577-594.e1 [PMID: 25066692 DOI: 10.1053/j.gastro.2014.06.043]
31. Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, Deng Y, Zhao J, Jiang S, Yuan Y, Wang HY, Cheng SQ, Xie D, Wang XF. TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell 2012; 22: 291-303 [PMID: 22975373 DOI: 10.1016/j.ccr.2012.07.023]
32. Akimaru K, Onda M, Tajiri T, Yoshida H, Yokomuro S, Mamada Y, Taniai N. Hypersplenism induced by hepatectomy. Hepatogastroenterology 2001; 48: 1170-1175 [PMID: 11490826]
33. Ferraz AA, Bacelar TS, Silveira MJ, Coelho AR, Câmara Neto RD, de Araújo Júnior JG, Ferraz EM. Surgical treatment of schistosomal portal hypertension. Int Surg 2001; 86: 1-8 [PMID: 11890333]
34. Lacerda CM, Freire W, Vieira de Melo PS, Lacerda HR, Carvalho G. Splenectomy and ligation of the left gastric vein in schistosomiasis mansoni: the effect on esophageal variceal pressure measured by a non-invasive technique. Keio J Med 2002; 51: 89-92 [PMID: 12125910]
35. Huang YH, Wu JC, Lui WY, Chau GY, Tsay SH, Chiang JH, King KL, Huo TI, Chang FY, Lee SD. Prospective case-controlled trial of adjuvant chemotherapy after resection of hepatocellular carcinoma. World J Surg 2000; 24: 551-555 [PMID: 10787075]
36. Ishikawa T, Higuchi K, Kubota T, Seki K, Honma T, Yoshida T, Kamimura T. Prevention of intrahepatic distant recurrence by transcatheter arterial infusion chemotherapy with platinum agents for stage I/II hepatocellular carcinoma. Cancer 2011; 117: 4018-4025 [PMID: 21365625 DOI: 10.1002/cncr.25989]